According to the WHO 2022 criteria, the diagnosis of NPM1-Ins AML can be made with lower blast counts; this is due to the previous observation that NPM1-Ins cases with lower blast percentage, classified as NPM1-mutated MDS, rapidly progress to AML with >20% blast counts [1,90,91]. The gene discussed is NPM1; the disease is myelodysplastic syndrome.